GSK-583

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的、选择性的、口服生物可利用的 RIPK2 激酶抑制剂，对人和大鼠 RIP2 的 IC50 分别为 5 nM 和 2 nM。

A potent, selective and orally bioavailable RIPK2 kinase inhibitor with IC50 of 5 nM and 2 nM for human and rat RIP2, respectively; displays robust selectivity against p38α and VEGFR2, and shows little or no inhibition of RIP3-dependent necroptotic cell death; potently and dose dependently inhibits MDP-stimulated TNFα production in human monocytes and human whole bolld with IC50 of 8 nM and 237 nM, respectively; inhibits MDP-induced inflammatory responses in vivo.

——

——

GSK583 | GSK 583

Apoptosis

RIP kinase

RIP1|RIP3

Inflammation/Immunology

——

1346547-00-9

398.4539

C20H19FN4O2S

>98% (HPLC)

DMSO: ≥ 37 mg/mL

FC1=CC2=C(NN=C2NC3=CC=NC4=CC=C(S(=O)(C(C)(C)C)=O)C=C34)C=C1

4-Quinolinamine, 6-[(1,1-dimethylethyl)sulfonyl]-N-(5-fluoro-1H-indazol-3-yl)-

(-20℃)

With Ice Pack

≥ 2 years